Perimeter Medical Imaging AI Announces Conference Call and Webcast to Discuss Second Quarter 2022 Financial Results and Provide Corporate Update
17 Agosto 2022 - 3:01PM
Business Wire
Hosting Call on Wednesday, August 24th at 5
pm ET
Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF)
(FSE:4PC) (“Perimeter” or the “Company”) – a medical technology
company driven to transform cancer surgery with
ultra-high-resolution, real-time, advanced imaging tools to address
high unmet medical needs – today announced it will report its
second quarter 2022 financial and operating results after the close
of U.S. financial markets on Wednesday, August 24, 2022.
Conference Call/Webcast
Information:
Date:
Wednesday, August 24, 2022
Time:
5:00 pm Eastern Time
Dial-In Number:
1-877-704-4453
International Dial-In:
1-201-389-0920
Conference ID:
13732303
Presenters:
Jeremy Sobotta, Chief Executive
Officer
Chris Scott, Chief Financial Officer
The call will also be broadcast live online through a
listen-only webcast, which will be posted on the Investors section
of the Company's website. The webcast will be archived on the
Company's investor relations webpage for at least 90 days. A
telephonic playback of the conference call will be available for 14
days after the conference call by calling 1-844-512-2921 or
1-412-317-6671 from abroad and referencing conference ID 13732303.
The above listed dates and times are subject to change.
About Perimeter Medical Imaging AI, Inc. Based in
Toronto, Canada and Dallas, Texas, Perimeter Medical Imaging AI
(TSX-V:PINK) (OTC:PYNKF) (FSE:4PC) is a medical technology company
driven to transform cancer surgery with ultra-high-resolution,
real-time, advanced imaging tools to address areas of high unmet
medical need. Available across the U.S., our FDA-cleared Perimeter
S-Series OCT system provides real-time, cross-sectional
visualization of excised tissues at the cellular level. The
breakthrough-device-designated investigational Perimeter B-Series
OCT with ImgAssist AI represents our next-generation, artificial
intelligence technology that is currently under clinical
development. The company’s ticker symbol “PINK” is a reference to
the pink ribbons used during Breast Cancer Awareness Month.
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward-Looking Statements This news release contains
statements that constitute “forward-looking information” within the
meaning of applicable Canadian securities legislation. In this news
release, words such as “may,” “would,” “could,” “will,” “likely,”
“believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,”
and similar words and the negative form thereof are used to
identify forward-looking statements. Forward-looking information
may relate to management’s future outlook and anticipated events or
results and may include statements or information regarding the
future financial position, business strategy and strategic goals,
competitive conditions, research and development activities,
projected costs and capital expenditures, research and clinical
testing outcomes, taxes and plans and objectives of, or involving,
Perimeter. Without limitation, information regarding the potential
benefits of Perimeter S-Series OCT, Perimeter B-Series OCT, and
Perimeter ImgAssist are forward-looking information.
Forward-looking statements should not be read as guarantees of
future performance or results, and will not necessarily be accurate
indications of whether, or the times at or by which, any particular
result will be achieved. No assurance can be given that any events
anticipated by the forward-looking information will transpire or
occur. Forward-looking information is based on information
available at the time and/or management’s good-faith belief with
respect to future events and are subject to known or unknown risks,
uncertainties, assumptions, and other unpredictable factors, many
of which are beyond Perimeter’s control. Such forward-looking
statements reflect Perimeter’s current view with respect to future
events, but are inherently subject to significant medical,
scientific, business, economic, competitive, political, and social
uncertainties and contingencies. In making forward-looking
statements, Perimeter may make various material assumptions,
including but not limited to (i) the accuracy of Perimeter’s
financial projections; (ii) obtaining positive results from trials;
(iii) obtaining necessary regulatory approvals; and (iv) general
business, market, and economic conditions. Further risks,
uncertainties and assumptions include, but are not limited to,
those applicable to Perimeter and described in Perimeter’s
Management Discussion and Analysis for the year ended December 31,
2021, which is available on Perimeter’s SEDAR profile at
www.sedar.com, and could cause actual events or results to differ
materially from those projected in any forward-looking statements.
Perimeter does not intend, nor does Perimeter undertake any
obligation, to update or revise any forward-looking information
contained in this news release to reflect subsequent information,
events, or circumstances or otherwise, except if required by
applicable laws.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220817005584/en/
Jodi Regts Perimeter Medical Imaging AI, Inc. Direct:
469-743-1834 Toll-free: 888-988-7465 (PINK) Investors:
investors@perimetermed.com Media: media@perimetermed.com
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Mar 2025 a Abr 2025
Simplify Exchang (NYSE:PINK)
Gráfica de Acción Histórica
De Abr 2024 a Abr 2025